In these circumstances, telaprevir should be stopped immediately. Initially, peginterferon and
ribavirin can be continued; however, if the
rash does not improve, all treatment should be stopped. Dermatology consultation is appropriate in this setting. Reported in less than 1% of telaprevir recipients, Stevens-Johnson syndrome (SJS) and drug rash with eosinophilia and systemic symptoms (DRESS) are medical emergencies.